Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIORITY: Sintilimab Plus Anlotinib in Resectable NSCLC
NCT06221462Phase 2Not yet recruiting
- Sponsor
- Ningbo No. 2 Hospital
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and anlotinib in non-small cell lung cancer (NSCLC), sponsored by Ningbo No. 2 Hospital. Primary endpoint: Major Pathological Response. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
sintilimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06221462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06221462.